Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2023
$148 million in new Medicare rebates for genetic testing
1 November 2023 - The Albanese Government is strengthening Medicare with a range of new Medicare rebates to ensure more ...
Posted by Michael Wonder on 31 Oct 2023
Basic health insurance to cover test that can predict return of breast cancer
30 October 2023 - A special test that predicts the chance of hormone-sensitive breast cancer returning will be added to ...
Posted by Michael Wonder on 31 Oct 2023
Democratic law makers call for insurance plans to fully cover over the counter birth control pill
30 October 2023 - Dozens of Democratic law makers are urging the Biden administration to require private health insurance plans ...
Posted by Michael Wonder on 31 Oct 2023
Australia a world leader in genetic screening as Medicare to provide free testing
31 October 2023 - Genetic carrier screening tests for three of the most devastating birth defects will soon be provided ...
Posted by Michael Wonder on 31 Oct 2023
Schedule of Pharmaceutical Benefits - 1 November 2023
1 November 2023 - The November 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Oct 2023
New Zealand Pharmaceutical Schedule - 1 November 2023
1 November 2023 - The November 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2023
PBS listing expanded to include treatment resistant high frequency episodic migraine
31 October 2023 - From 1 November 2023, Australians with treatment resistant high frequency episodic migraine will have access to fremanezumab ...
Posted by Michael Wonder on 31 Oct 2023
End of temporary funding of palivizumab for preventing RSV
31 October 2023 - Palivizumab has been funded for the last two seasons from funding made available as part of the ...
Posted by Michael Wonder on 30 Oct 2023
Expanded access to chronic heart failure treatment on the PBS
30 October 2023 - More Australians with chronic heart failure will have access to subsidised treatment under the PBS. ...
Posted by Michael Wonder on 29 Oct 2023
100,000 patients eligible for heart drug under PBS
28 October 2023 - Almost 100,000 patients are set to save hundreds of dollars per year as access to a ...
Posted by Michael Wonder on 27 Oct 2023
Organon Canada announces availability of a high concentration, citrate free formulation of Hadlima, a biosimilar to Humira
26 October 2023 - Hadlima 40 mg/0.4 mL offers a higher concentration compared to Hadlima 40 mg/0.8 mL. ...
Posted by Michael Wonder on 27 Oct 2023
Legislation expands access to breakthrough Alzheimer’s treatment
26 October 2023 - There’s new hope in the fight against Alzheimer’s. Federal legislation called the Access to Innovative Treatments ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 23 Oct 2023
Life changing gene therapy for babies with spinal muscular atrophy
23 October 2023 - The Australian Government is giving more families access to life changing gene therapy for spinal muscular atrophy ...